Photo of Andrew Do

Andrew Do

Andrew’s practice focuses on FDA-regulated food and drug products, with particular emphasis on regulatory policy, enforcement, and government engagement. He advises companies, trade associations, and private equity clients on FDA and Administration priorities affecting foods, dietary supplements, and drugs. He helps clients navigate complex regulatory and political landscapes by developing advocacy strategies, responding to competitive threats and enforcement risks, and positioning products and business priorities before regulators and policymakers.

He counsels clients on compliance with FDA requirements, drafts regulatory comments and other advocacy materials, develops strategies to address competitive and market access challenges, assesses consumer litigation risks, and provides ongoing intelligence to help clients anticipate and respond to evolving legal and policy developments. His work also includes advocacy before FDA on regulatory and policy matters, enforcement actions, and the Agency’s exercise of enforcement discretion. Andrew further advises pharmaceutical companies on drug pricing and market access, translating complex policy and regulatory priorities into strategic, actionable guidance to support clients at the intersection of FDA and CMS.

His practice includes FDA regulatory due diligence and transaction support for acquisitions, investments, and exits, as well as advising trade associations on policy priorities, coalition development, and industry engagement initiatives. He helps clients navigate legislative and Administration priorities and engages with individuals on Capitol Hill and across the Executive Branch. He also advises clients on stakeholder dynamics, emerging consumer and patient advocacy trends, and market dynamics that may affect business objectives.

Drawing on his scientific training and experience at FDA, Andrew brings a policy-oriented, technically informed approach to positioning products, arguments, and narratives before regulators, legislators, and the public to achieve practical business outcomes.

On November 6, U.S. Senator Roger Marshall (R-KS), a member of the Senate Health, Education, Labor, and Pensions (HELP) Committee and MAHA Caucus, introduced the highly anticipated “Better Food Disclosure Act” (the “Better FDA Act”). The bill aims to close the so-called “GRAS loophole.” Although the bill, which was developed…

Continue Reading Senator Marshall Proposes an Overhaul of the GRAS Framework

On September 9, President Trump’s Make America Healthy Again (MAHA) Commission, chaired by HHS Secretary Kennedy, released its “Make Our Children Healthy Again Strategy Report” (Strategy Report) as directed by Executive Order 14212 (EO), which established the MAHA Commission. A draft of this report was leaked to the public about…

Continue Reading The Make Our Children Healthy Again Strategy Report: What it Says and Doesn’t Say about U.S. Food Regulation

Over the last week or so there have been several developments from the Trump Administration and Congress affecting the food industry. We outline several of those developments below and identify key ways industry stakeholders can engage.

Click here to read the full alert on cov.com.

Continue Reading In Case You Missed It: Recent Food-Related Developments from the Trump Administration and Congress

On May 16, 2023, FDA released a draft compliance policy guide (“draft CPG”) for major food allergen labeling and cross-contact, which updates the 2005 CPG Sec 555.250 Statement of Policy for Labeling and Preventing Cross-contact of Common Food Allergens. CPGs are intended to advise FDA staff, including investigators, of the agency’s strategy for assessing and enforcing industry compliance. The draft CPG contains FDA’s current policies on major food allergen labeling requirements, allergen cross-contact, voluntary allergen information (e.g., advisory label statements), thresholds, and regulatory actions. The draft CPG is more comprehensive than the 2005 CPG and is intended to create a uniform standard and minimize the possibility that individual FDA staff will follow differing regulatory approaches.    

The draft CPG details the allergen labeling requirements of the Federal Food, Drug, and Cosmetic Act. We do not discuss those requirements here, but instead focus on the policies the draft CPG discusses that are not addressed, in detail, in other FDA allergen documents, such as the recent draft guidance, Questions and Answers Regarding Food Allergens, Including the Food Allergen Labeling Requirements of the Federal Food, Drug, and Cosmetic Act.

I. Allergen Cross-Contact

Allergen cross-contact is the unintentional incorporation of a food allergen into a food that does not contain that allergen as an ingredient. The draft CPG notes that the likelihood an allergen will be present due to cross-contact can be impacted by factors such as the characteristics of the food, the distribution of the allergen within a food (homogeneous versus particulate), the type of manufacturing process, the equipment used, and the cleaning procedures applied (e.g., dry cleaning versus wet cleaning). While FDA acknowledges these factors, the agency states that cross-contact may occur due to practices such as the failure to clean shared equipment adequately or segregate allergens properly, improper rework addition, or improper production scheduling. The draft CPG does not explicitly acknowledge that even with adequate CGMPs, sanitation, and preventive controls, cross-contact can still occur.

The draft CPG also confirms FDA’s position that “[m]ajor food allergens unintentionally incorporated into a food are not to be declared in the ingredient list or the ‘Contains’ statement.”

Continue Reading FDA Issues Draft Compliance Policy Guide for Major Food Allergen Labeling and Cross-Contact

On January 31, 2023, FDA Commissioner Robert M. Califf announced a proposed redesign of the human foods program at FDA. The proposal follows the findings and recommendations of a Reagan-Udall Foundation expert panel that Dr. Califf had charged with evaluating the agency’s existing human foods program. Commissioner Califf called the…

Continue Reading FDA Plans to Redesign the Human Foods Program